Explain this page
Arphra AIPlain-English read on Corcept Therapeutics Incorporated’s valuationIncome statement
| In USD | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & profit | |||||||||
| Revenue | $365.98M | $401.86M | $482.38M | $675.04M | $761.41M | $976.58M | $1.37B | $1.91B | $2.62B |
| Cost of revenue | $5.28M | $5.39M | $6.48M | $10.88M | $12.98M | $15.2M | $21.51M | $29.96M | $41.72M |
| Gross profit | $360.7M | $396.47M | $475.89M | $664.16M | $748.43M | $945.68M | $1.34B | $1.9B | $2.54B |
| Gross margin | +98.56% | +98.66% | +98.66% | +98.39% | +98.30% | +96.84% | +98.27% | +99.35% | +97.16% |
| Operating | |||||||||
| Research & development | $113.86M | $130.99M | $184.35M | $246.89M | $254.91M | $361.72M | $504.45M | $698.98M | $922.92M |
| Selling, general & administrative | $122.36M | $152.85M | $184.26M | $280.32M | $448.73M | $456.78M | $643.14M | $866.3M | $1.22B |
| Total operating expenses | $236.22M | $283.84M | $368.61M | $527.21M | $703.63M | $824.24M | $1.15B | $1.57B | $2.14B |
| Operating income | $124.48M | $112.63M | $107.28M | $136.95M | $44.8M | $157.14M | $225.96M | $317.73M | $421.4M |
| Operating margin | +34.01% | +28.03% | +22.24% | +20.29% | +5.88% | +16.09% | +16.52% | +16.60% | +16.10% |
| EBITDA | $127.95M | $113.89M | $108.32M | $138.29M | $46.69M | $156.25M | $225.73M | $304.14M | $433.44M |
| EBIT | $125.01M | $112.63M | $107.28M | $136.95M | $44.8M | $156.3M | $223.4M | $310.39M | $433.09M |
| Below the line | |||||||||
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest income | $529K | $3.56M | $17.28M | $24.54M | $0 | $23.66M | $32.98M | $46.45M | $63.21M |
| Other income / expense | $529K | $3.56M | $17.28M | $24.54M | $21.67M | — | — | — | — |
| Pre-tax income | $125.01M | $116.19M | $124.56M | $161.49M | $66.46M | $193.77M | $260.82M | $375.7M | $511.19M |
| Income tax expense | $12.49M | $14.77M | $18.42M | $20.28M | -$33.19M | $25.72M | $37.26M | $50.35M | $71.71M |
| Earnings | |||||||||
| Net income | $112.51M | $101.42M | $106.14M | $139.73M | $99.65M | $155.24M | $214.17M | $301.71M | $416.28M |
| Net income · continuing ops | $112.51M | $101.42M | $106.14M | $141.21M | $99.65M | $178.65M | $260.38M | $354.4M | $488.27M |
| Net margin | +30.74% | +25.24% | +22.00% | +20.70% | +13.09% | +15.90% | +15.66% | +15.77% | +15.91% |
| EPS · basic | $0.97 | $0.95 | $1.02 | $1.35 | $0.95 | $0.64 | $2.95 | $5.96 | $10.57 |
| EPS · diluted | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 | $0.58 | $2.61 | $5.42 | $9.46 |
| EPS · low estimate | — | — | — | — | — | $0.31 | $0.41 | $3.16 | $7.65 |
| EPS · high estimate | — | — | — | — | — | $0.88 | $6.19 | $6.75 | $11.97 |
| Shares · basic | 115.65M | 106.79M | 103.56M | 103.23M | 103.86M | 103.33M | 103.89M | 103.66M | 102.87M |
| Shares · diluted | 125.96M | 115.97M | 111.74M | 113.48M | 119.99M | 120.97M | 121.09M | 121.08M | 119.64M |
| Coverage | |||||||||
| Analysts (revenue) | — | — | — | — | — | 4 | 4 | 5 | 2 |
| Analysts (EPS) | — | — | — | — | — | 4 | 4 | 3 | 1 |
Coverage notes. Historical figures come’s as-reported income statements / balance sheets / cash flows in our data warehouse. Forecast columns (italicised, faint accent tint) carry vendor-supplied numbers where available (revenue + EPS consensus) and ratio-derived values for every other line. Margins / ratios are the trailing-3y average from history applied to the forecast revenue; values are clamped to enforce P&L identity (gross ≥ operating, EBITDA ≥ operating, net ≤ operating) and balance-sheet identity (assets = liabilities + equity by construction). Cash-flow FCF reconciles to OCF + CapEx. USD conversion uses the period-end close of the issuer's reported/USD pair from forex_prices_daily; share counts stay unconverted.
Financials
Full income statement, balance sheet, and cash-flow history is included with Pro.
Upgrade to Pro